Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistance

Fig. 5

Alternative splicing in targeted therapy resistance. SRSF3 enhances the splicing event of MDM4 to combine with p53. SRSF6 regulates the splicing event of Bim. Both of them can assist BRAF inhibitors to block the process of the dimerization of BRAF and the combination with MEK. Conversely, NRAS increases resistance to BRAF inhibitors through aberrant splicing to generate isoforms II and V

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us